Obstructive sleep apnea (OSA) is characterized by recurrent episodes of complete or partial upper airway occlusion during sleep, despite ongoing efforts to breathe, associated with repetitive episodes of oxygen desaturation and arousals with sleep fragmentation. 1 The prevalence of OSA is estimated at 10% to 17% for men and 3% to 9% for women among adults in the Western countries. 2 Obstructive sleep apnea is diagnosed by polysomnography (PSG) and is treated by continuous positive airway pressure (CPAP), oral appliances, surgery, and weight loss.
Obstructive sleep apnea negatively affects the quality of life with mood, behavioral, and cognitive deficits, leading to impaired work performance and productivity. 3 It also increases the frequency of automobile and occupational accidents and is associated with impaired glucose homeostasis, as well as increased cardiovascular and cerebrovascular morbidity and mortality. [4] [5] [6] A biomarker for the evaluation of OSA disease severity, prognosis, and response to treatment with the ability to predict future cardiovascular events is necessary. 7 Carotid atherosclerosis (CA) is a dynamic process, characterized by arterial wall stiffness, accompanied by various anatomical and physiological changes. A useful early index of CA and cardiovascular events is carotid intima-media thickness (cIMT). 8 Indeed, in a systematic review and meta-analysis including 14 studies with 45 828 asymptomatic individuals who underwent onetime cIMT measurement at baseline (median follow-up: 10.8 years), the hazard ratio (per 0.10 mm adjusted mean common cIMT difference) for first myocardial infarction and stroke was 1.09 (95% confidence interval [CI]: 1.07-1.12), for first myocardial infarction was 1.08 (95% CI: 1.05-1.10), and for first stroke was 1.12 (95% CI: 1.10-1.15). 9 However, numerous risk factors have been associated with cIMT enhancement, OSA being one of them.
In this issue of the journal, Zhou et al 10 have reviewed current data and conducted a meta-analysis on the association between OSA and cIMT among adult patients examined with PSG. They included 18 different studies with 2095 carotid artery measurements (1896 patients). Overall, a significantly higher cIMT was demonstrated in patients with OSA (P < .001), although there was significant heterogeneity. 10 However, no linear correlation between apnea hypopnea index (AHI) and cIMT was demonstrated. Conversely, the authors proposed a threshold effect-the increase in cIMT was only significant if AHI excluded a certain hitherto unknown threshold value. 10 Certainly, this study has its limitations, as acknowledged by the authors. The first relates to the use of ultrasonography for the evaluation of cIMT. Indeed, this technique is highly dependent on the experience of the sonographer and, hence, less objective than magnetic resonance imaging. Second, several types of publications were excluded. Furthermore, some of the included studies recruited patients with comorbidities and various medications. 10 In this context, more information on adjustment for such comorbidities and vascular risk factors (for instance, hypertension, dyslipidemia, obesity, smoking, and diabetes), which are relevant both to cIMT 8, 9 and OSA, 6 would have been welcomed.
Nonetheless, the strength of the analysis is the clear and useful clinical message. Indeed, patients with severe OSA are at high risk of both increased cIMT and cardiovascular events. In such patients, routine carotid artery screening could suggest early intervention to address risk factors for vascular disease and reduce vascular events. 11 In OSA, cIMT measurement could prove helpful as an end point in future interventional clinical trials. For example, it may provide an additional argument to promote adherence to CPAP treatment, as already shown with inflammatory 12 parameters, metabolic 13, 14 risk factors, and cardiovascular end points. 15 Finally, given the importance of cIMT as a marker of generalized and progressive vascular damage, [16] [17] [18] [19] [20] these new observations 10 lend further support to the concept that OSA is associated with vascular disease.
In conclusion, the meta-analysis by Zhou et al 10 has provided evidence that OSA is an independent risk factor for cIMT. This needs to be born in mind when treating patients with OSA and adds to the increasing responsibilities of clinicians 21 in this setting.
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